Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque …
Oversubscribed round demonstrates strong investor confidence in Lin Health's neuroscience-based approach to chronic painDENVER, Dec. 9, 2025 /PRNewswire/ -- Lin…
Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer's disease treatmentsHighlighted clinical…
A first-of-its-kind scientific expedition examines the next era of precision mental healthcare, psychedelic science and psychedelic-assisted therapy, and AI-driven clinical…
VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is advancing…
NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Imre today announced the appointment of Nadine Lafond as its new Chief Executive…
Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatmentsHighlighted…
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)…
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1…
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire…